Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis-Reference-Cited by-同舟云学术

Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis

Published:2023-09 Issue: Volume:119 Page:102586
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Becherini Carlotta,Visani Luca,Caini Saverio,Bhattacharya Indrani S.,Kirby Anna M.,Nader Marta Gustavo,Morgan Gilberto,Salvestrini Viola,Coles Charlotte E.,Cortes Javier,Curigliano Giuseppe,de Azambuja Evandro,Harbeck Nadia,Isacke Clare M.,Kaidar-Person Orit,Marangoni Elisabetta,Offersen Birgitte,Rugo Hope S.,Morandi Andrea,Lambertini Matteo,Poortmans Philip,Livi Lorenzo,Meattini Icro^ORCID

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Reference55 articles.

1. Palbociclib and letrozole in advanced breast cancer;Finn;N Engl J Med,2016

2. The Effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: A Randomized Clinical Trial;Sledge;JAMA Oncol,2020

3. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer;Hortobagyi;Ann Oncol,2019

4. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE);Johnston;J Clin Oncol,2020

5. Overall survival with palbociclib and fulvestrant in advanced breast cancer;Turner;N Engl J Med,2018

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment;Drug Resistance Updates;2024-09

2. Targeted RT study: results on early toxicity of targeted therapies and radiotherapy;Radiation Oncology;2024-08-29

3. Cyclin-dependent kinase 4/6 inhibitors combined with stereotactic ablative radiotherapy in oligometastatic HR-positive/HER2-negative breast cancer patients;British Journal of Radiology;2024-08-09

4. Locoregional Radiotherapy in Patients with Advanced Breast Cancer Treated with Cyclin-Dependent Kinase 4/6 Inhibitors Based on Real-World Data;Pharmaceuticals;2024-07-11

5. Concurrent Use of Abemaciclib and Radiotherapy in Metastatic Breast Cancer Patients: A Single-Center Experience;Chemotherapy;2024-06-13